Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Business Wire

Published

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinatio

Full Article